Trillium Asset Management LLC Lowers Holdings in Omnicell, Inc. $OMCL

Trillium Asset Management LLC decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 4.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 137,613 shares of the company’s stock after selling 5,660 shares during the quarter. Trillium Asset Management LLC owned 0.29% of Omnicell worth $4,046,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in OMCL. Principal Financial Group Inc. lifted its stake in Omnicell by 2.6% in the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company’s stock worth $8,553,000 after acquiring an additional 6,288 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock worth $58,745,000 after acquiring an additional 154,038 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Omnicell in the first quarter worth approximately $2,073,000. Wakefield Asset Management LLLP lifted its stake in Omnicell by 8.1% in the first quarter. Wakefield Asset Management LLLP now owns 25,517 shares of the company’s stock worth $892,000 after acquiring an additional 1,906 shares during the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Omnicell in the first quarter worth approximately $10,542,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 3,880 shares of the company’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the sale, the executive vice president owned 110,653 shares in the company, valued at $3,679,212.25. This represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is currently owned by company insiders.

Analyst Ratings Changes

OMCL has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, July 21st. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Benchmark boosted their price objective on shares of Omnicell from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $42.00.

Omnicell Stock Up 3.6%

OMCL stock opened at $35.74 on Thursday. The company has a fifty day moving average price of $31.45 and a 200 day moving average price of $30.27. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $53.31. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 71.48, a price-to-earnings-growth ratio of 6.29 and a beta of 0.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.36 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $310.63 million during the quarter, compared to the consensus estimate of $295.59 million. During the same quarter in the prior year, the firm earned $0.56 EPS. Omnicell’s revenue for the quarter was up 10.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.630-1.730 EPS. Q4 2025 guidance at 0.400-0.500 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.